Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia
© Karapanagiotidis et al; licensee BioMed Central Ltd. 2009
Received: 25 July 2009
Accepted: 03 November 2009
Published: 03 November 2009
Matrix metalloproteinases (MMPs) constitute a family of zinc-dependent proteases (endopeptidases) whose catalytic action is the degradation of the extracellular matrix components. In addition, they play the major role in the degradation of collagen and in the process of tissue remodeling. The present clinical study investigated blood serum levels of metalloproteinases- 1, -2, -3 and -9 in patients with acute and chronic aortic dissection, thoracic aortic aneurysm and acute myocardial ischemia compared to healthy individuals.
The blood serum levels of MMP-1, -2, -3 and -9 were calculated in 31 patients with acute aortic dissection, 18 patients with chronic aortic dissection, 18 patients with aortic aneurysm and in 13 patients with acute myocardial ischemia, as well as in 15 healthy individuals who served as the control group. Serum MMP levels were measured by using an ELISA technique.
There were significantly higher levels of MMP-3 in patients with acute myocardial ischemia as compared to acute aortic dissection (17.33 ± 2.03 ng/ml versus 12.92 ± 1.01 ng/ml, p < 0.05). Significantly lower levels of MMP-1 were found in healthy controls compared to all groups of patients (1.1 ± 0.38 ng/ml versus 2.97 ± 0.68 in acute aortic dissection, 3.09 ± 0.98 in chronic dissection, 3.16 ± 0.51 in thoracic aortic aneurysm and 4.58 ± 1.04 in acute myocardial ischemia, p < 0.05). Higher levels of MMP-1 and MMP-3 were detected on males. There was a positive correlation with increasing age (r = 0.38, p < 0.05). In patients operated for acute type A aortic dissection, the levels of MMP-1, MMP-3 and MMP-9 increased immediately after surgery, while the levels of MMP-2 decrease. At 24 hours postoperatively, levels of MMP -1, -2 and -9 are almost equal to the preoperative ones.
Measurement of serum MMP levels in thoracic aortic disease and acute myocardial ischemia is a simple and relatively rapid laboratory test that could be used as a biochemical indicator of aortic disease or acute myocardial ischemia, when evaluated in combination with imaging techniques.
Matrix metalloproteinases (MMPs) constitute a large family of proteolytic enzymes containing a metal in their organic structure playing key roles in degradation of proteins in extracellular matrix and in tissue remodeling through complicated biological procedures [1–3]. This double action has been proven to be involved in the pathology of serious cardiovascular diseases, such as aortic aneurysm, dissection and coronary artery disease, which constitute the most common cause of death in developed countries [4–6].
In all the above pathological processes, but mostly in acute aortic dissection, a complex process is initiated for the repair and remodeling of the involved aortic wall. This process includes thrombus degradation through fibrinolytic activity and proteolysis of the extracellular matrix [7–9]. MMPs are proteolytic enzymes, specifically endopeptidases, whose catalytic mechanism involves a metal ion such as zinc (Zn2+) and calcium (Ca2+) . Metalloproteinases, also called matrixins, include a large family of proteolytic enzymes, known as metzincin super-family. Their catalytic action is the degradation, mainly in neutral pH environment, of all proteins of the extracellular matrix . In addition, they modulate many bioactive molecules at the cell surface and can act in concept to influence cell behaviour such as angiogenesis, migration, reproduction and immune system activity .
A number of metalloproteinases have been identified in blood serum that are categorized mainly in four groups: a) collagenases (MMP-1, MMP-8, MMP-13, MMP-18), b) gelatinases (MMP-2, MMP-9) c) stromelysins (MMP-3, MMP-10) and d) membrane-bound metalloproteinases (MMP-14, MMP-15, MMP-16, MMP-17, MMP-24, MMP-25) .
The aim of our study is to evaluate the levels of serum MMP-1, -2, -3 and -9 in acute and chronic aortic dissection, thoracic aortic aneurysm and acute myocardial ischemia compared to normal individuals and assess their clinical significance.
Demographic characteristics of the study groups
(n = 31)
(n = 18)
(n = 18)
(n = 13)
(n = 15)
Age mean ± SD
60.1 ± 14.8
60.6 ± 13.1
60.7 ± 13.7
65.4 ± 10.3
40.1 ± 5.2
Arterial hypertension (%)
Chest pain (%)
Creatinine > 140 μmol/l (%)
Exclusion criteria included the presence of abdominal aortic aneurysm, use of corticosteroid or non-steroid anti-inflammatory medication, or a history of chronic pulmonary disease or malignancy of any type. All these clinical conditions have been associated with elevated levels of serum MMPs [5, 11].
The following MMPs were measured in the blood serum of all individuals: MMP-1 (interstitial collagenase) as representative of collagenases, MMP-3 (stromelysin 1) as representative of stromelysins, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) as representatives of gelatinases. Blood samples in group A were collected after diagnosis of acute aortic dissection was established mainly with computed tomography angiography and before any surgical intervention in case of Stanford A dissection. Seventeen patients in this group (50%), who were diagnosed with a Stanford A dissection, were operated for aortic root replacement. In these patients serial MMP serum levels were also calculated just after transfer of the patient from theater to ICU and at 12 and 24 hours postoperatively. Blood samples in groups B and C were collected before any surgical intervention (open or endovascular). Blood samples in group D were collected at the onset of acute thoracic pain.
All blood samples were collected through a central venous or peripheral catheter and centrifuged at 4,000 rpm. Then, the centrifuged serum samples were refrigerated at -27°C and stored until final analysis. Serum MMP levels were measured by using a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) test (R&D Systems Europe, Abingdon, UK) according to the manufacturer's guidelines. All samples were measured as duplicates. The mean was calculated for data analysis. The levels of MMPs were determined according to a known curve which takes into account four parameters based on the following equation: 4 parameter- (y = (A-D)/(1+(x/C)^B)+D) and the use of 7 values as standards for the calculation of the standard curve. All MMPs values were measured as ng/ml.
All data are presented as mean ± standard error. Quantitative variables were tested for normality of their distribution by the Kolmogorov-Smirnov test. For non-parametric quantitative variables, data were subjected to Kruskal-Wallis analysis and tested with Mann-Whitney U test, while for qualitative variables the chi-square test was used. The Spearman's test was used for regression analysis. Analyses were performed using the SPSS statistical package (version 11.5 for Windows). Differences were considered significant if p values were lower than 0.05.
The levels of metalloproteinases (ng/ml) in studied groups of patients and healthy individuals
Mean value ± St. error
Acute aortic dissection
2.97 ± 0.68
Chronic aortic dissection
3.09 ± 0.98
3.16 ± 0.51
4.58 ± 1.04
1.10 ± 0.38
2.95 ± 0.34
Acute aortic dissection
151.62 ± 6.82
Chronic aortic dissection
172.12 ± 11.79
156.64 ± 9.16
180.94 ± 15.49
171.37 ± 11.39
163.59 ± 4.58
Acute aortic dissection
12.92 ± 1.01
Chronic aortic dissection
17.50 ± 3.60
17.64 ± 3.64
17.33 ± 2.03
10.66 ± 1.77
14.93 ± 1.11
Acute aortic dissection
412.93 ± 89.85
Chronic aortic dissection
469.86 ± 56.57
342.97 ± 74.66
409.74 ± 83.35
400.13 ± 77.90
408.00 ± 37.78
Comparison of the levels (ng/ml) of metalloproteinases in all groups according to sex
Sex of patient
Mean value ± St. error
3.44 ± 0.45
1.60 ± 0.29
165.60 ± 55.64
157.80 ± 17.38
17.40 ± 1.38
8.03 ± 0.58
437.53 ± 47.40
325.33 ± 52.69
MMP-1 serum levels in healthy individuals (group E) were significantly lower when compared to those observed in all other groups (p < 0.05). MMP-3 serum levels in healthy individuals (group E) were also found to be lower compared to the other groups, however this difference did not reach statistical significance. As far as the levels of MMP-2 and MMP-9 are concerned, serum levels were similar between groups.
Furthermore, blood serum levels of MMP-3 in patients with acute aortic dissection were significantly lower compared to those found in patients with acute myocardial ischemia (12.92 ± 1.10 versus 17.33 ± 2.03 ng/ml, p < 0.05). Mean values of MMP-1, MMP-2 and MMP-9 did not show significant difference between groups A and D. In addition, levels of MMP-1, -2, -3, -9 were not statistically different in patients with chronic aortic dissection (group B), aortic aneurysm (group C) and healthy individuals (group E).
Variability in acute aortic dissection of the levels (ng/ml) of metalloproteinases before the surgical intervention, immediately after, at 12 and 24 hours after the intervention
Before surgical intervention
12 hours post-op
24 hours post-op
3.73 ± 0.90
8.92 ± 3.92
6.62 ± 1.52
3.38 ± 1.25
152.61 ± 9.92
132.72 ± 5.18
117.23 ± 7.14
134.02 ± 8.06
12.39 ± 1.34
13.52 ± 1.14
23.71 ± 4.46
29.50 ± 6.25
408.16 ± 142.57
616.65 ± 70.35
120.96 ± 19.15
123.36 ± 33.93
Matrix metalloproteinases play a significant role in the pathogenesis of aortic disease. The present study evaluated the levels of serum MMPs- 1, -2, -3 and -9 in patients with diseases of the thoracic aorta. These were compared with values obtained from patients with acute myocardial ischemia and from normal individuals.
The levels of MMP-1 were found to be lower in healthy individuals compared to patients with acute and chronic aortic dissection, aortic aneurysm and myocardial ischemia. Atherosclerosis is the main common pathologic finding in these disorders. Clinical studies have investigated the role of MMP-1 in this pathologic process [6, 14, 15]. These studies evaluated the levels of MMP-1 in the vessel's wall and not in blood serum as performed in the present study.
Kai et al. measured the levels of MMPs-2 and -9 in the blood serum of patients with acute myocardial ischemia and they revealed a significant increase compared to healthy individuals . This is in contradiction with the results of the present study. Nambi et al. investigated the levels of MMP-1 in patients with coronary artery disease . They have not found any difference and concluded that MMP-1 can not be used as a prognostic biomarker for coronary artery disease. On the contrary, we observed that mean values of MMP-1 in patients with acute myocardial ischemia were significantly higher compared to the control group. This difference can be attributed to the fact that patients in our study suffered from acute myocardial ischemia, and not chronic stable coronary artery disease. In addition, healthy individuals in the present study were of younger age which may have affected their MMP-1 levels.
MMP-1 levels in our study showed a positive correlation with age, a finding that has not been previously reported in the literature. In addition, the levels of MMP-1 were found to be significantly higher in men compared to women in all study groups. To the best of our knowledge, gender variability of MMP-1 has not been previously investigated in the literature.
As far as MMP-3 is concerned, it was found that the MMP-3 levels in patients with acute myocardial ischemia were significantly higher than those found in patients with acute aortic dissection. In many occasions patients with acute aortic dissection present with clinical and electrocardiographic signs that mimic myocardial ischemia, which make differential diagnosis difficult . Numerous studies have reported high levels of MMP-3 in atherosclerotic plaques in any kind of aortic aneurysm [15, 19, 20]. High levels of MMP-3 have also been reported in the blood serum of patients with coronary arteries aneurysm . MMP-3, as well as MMP-9, has been implicated in the pathogenesis and treatment of abdominal aortic aneurysms [22, 23]. In a recent study by Monaco et al. it was found that the levels of MMP-3 in the blood serum decreased after endovascular repair of descending thoracic aortic aneurysms . In addition, our study found that MMP-3, as also shown with MMP-1 levels, is increased in the blood serum of men compared to women in all groups.
The present study also investigated the pattern of change in the levels of the four metalloproteinases after surgical intervention in patients operated for acute aortic dissection. It was found that, immediately after the intervention, the levels of MMP-1, MMP-3 and MMP-9 are increased, while the levels of MMP-2 are decreased. At 24 hours postoperatively, levels of MMP -1, -2 and -9 are almost equal to the preoperative ones. Sangiorgi et al. found that after endovascular exclusion MMP-9 and MMP-3 levels decreased to a level similar to that of patients undergoing open repair . The cardiopulmonary bypass has also been reported to affect serum levels of MMPs . Therefore, duration of extracorporeal circulation is a factor that has to be considered when studying the levels of MMPs after surgical intervention.
As a conclusion, measurement of serum MMP levels in thoracic aortic disease and acute myocardial ischemia is a simple and relatively rapid laboratory test, which can be easily obtained even in the primary healthcare setting. Although increased MMP-1 and -3 levels are not specific and can not provide a definite clinical diagnosis, they can be used as a biochemical indicator of aortic disease or acute myocardial ischemia, when evaluated in combination with imaging techniques, such as computed tomography, magnetic resonance angiography or echocardiography. The concept of biochemical diagnosis of aortic dissection is an attractive option, as it is rapid, non-invasive, easy to perform and conceivably less costly than contemporary imaging studies. Further studies are required in order to draw precise conclusions on the clinical significance of MMP serum levels in diagnosis and monitoring of different therapeutic strategies in the management of cardiovascular diseases.
Dr Christina Aggouridaki, Vassiliki Tsavdaridou and Constantinos Tomos performed the ELISA biochemical analysis. Dr Ioannis Karapanagiotidis contributed to the statistical analysis of the results.
- Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993, 4: 197-250.PubMedGoogle Scholar
- Galis ZS and Khatri JJ: Matrix metalloproteinases in vascular remodelling and atherogenesis: The good, the bad, and the ugly. Circulation Research. 2002, 90: 251-62.PubMedGoogle Scholar
- Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res. 2003, 92: 827-839. 10.1161/01.RES.0000070112.80711.3D.View ArticlePubMedGoogle Scholar
- Isselbacher EM: Thoracic and abdominal aortic aneyrysms. Circulation. 2005, 111: 816-828. 10.1161/01.CIR.0000154569.08857.7A.View ArticlePubMedGoogle Scholar
- Dollery CM, McEwan JR, Henney A: Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995, 7: 863-8.View ArticleGoogle Scholar
- Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrade activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994, 94: 2493-503. 10.1172/JCI117619.View ArticlePubMedPubMed CentralGoogle Scholar
- Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K: Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J. 2001, 65: 71-75. 10.1253/jcj.65.71.View ArticlePubMedGoogle Scholar
- Toshiharu I, Noriko A: Collagen and elastin degradation by matrix metalloproteinase in aortic dissection. Hum Pathol. 2000, 31: 640-646. 10.1053/hupa.2000.7642.View ArticleGoogle Scholar
- Lijnen HR: Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb. 2004, 33: 275-281. 10.1159/000083814.View ArticleGoogle Scholar
- Woessner JF: Matrix metalloproteinases inhibition: from the Jurassic to the third millennium. Ann NY Acad Sci. 1999, 878: 388-10.1111/j.1749-6632.1999.tb07697.x.View ArticlePubMedGoogle Scholar
- Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem. 1999, 274: 21491-94. 10.1074/jbc.274.31.21491.View ArticlePubMedGoogle Scholar
- Matrisian LM: The matrix degrading metalloproteinases. Bioessays. 1992, 14: 455-463. 10.1002/bies.950140705.View ArticlePubMedGoogle Scholar
- Murphy G, Nagase H: Progress in matrix metalloproteinases research. Mol Asp Med. 2008, 29: 290-308. 10.1016/j.mam.2008.05.002.View ArticleGoogle Scholar
- Montero I, Orbe J, Varo N, Beloqui O, Monreal JI, Rodríguez JA, Díez J, Libby P, Páramo JA: C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006, 47: 1369-78. 10.1016/j.jacc.2005.10.070.View ArticlePubMedGoogle Scholar
- Orbe J, Fernandez L, Rodriguez JI, Rabago G: Different expressions of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis. 2003, 170: 269-76. 10.1016/S0021-9150(03)00251-X.View ArticlePubMedGoogle Scholar
- Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998, 32: 368-72. 10.1016/S0735-1097(98)00250-2.View ArticlePubMedGoogle Scholar
- Nambi V, Morrison A, Hoogeveen RC, Coresh J, Miles S, Rhodes CE, Sharrett AR, Boerwinkle BE, Ballantyne CM: Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease. Tex Heart Inst J. 2008, 35: 388-94.PubMedPubMed CentralGoogle Scholar
- Mir MA: Aortic dissection - in pursuit of a serum marker. Am J Emerg Med. 2008, 26: 942-45. 10.1016/j.ajem.2007.12.012.View ArticlePubMedGoogle Scholar
- Newman KM, Ogata Y, Malon AM, Irizarry E, Gandhi RH, Nagase H, Tilson MD: Identification of matrix metalloproteinases-3 and -9 in abdominal aneurysm. Arterioscler Thromb. 1994, 14: 1315-8.View ArticlePubMedGoogle Scholar
- Carrell TW, Burnard KG, Wells GM, Clements JM, Smith A: Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation. 2002, 105: 477-82. 10.1161/hc0402.102621.View ArticlePubMedGoogle Scholar
- Tengiz I, Ercan E, Aliyev E, Sekuri C, Duman C, Altuglu I: Elevated levels of matrix metalloproteinase-3 in patients with coronary aneurysm: A case control study. Cur Contr Tr Cardiovasc Med. 2004, 5: 1-10. 10.1186/1468-6708-5-1.View ArticleGoogle Scholar
- Keeling WB, Armstrong PA, Stone P, Bandyk DF, Shames ML: An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms. Vasc Endovasc Surg. 2005, 39: 457-64. 10.1177/153857440503900601.View ArticleGoogle Scholar
- Sangiorgi G, D'Averio R, Mauriello A, Bondio M, Pontillo M, Castelvecchio S, Trimarchi S, Tolva T, Nano G, Rampoldi V, Spagnoli LG, Inglese L: Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment. Circulation. 2001, 104 (suppl 1): 288-295.Google Scholar
- Monaco M, Stassano P, DiTomasso L, Iannelli G: Response of plasma matrix metalloproteinases and tissue inhibitor of metalloproteinases to stent-graft surgery for descending thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2007, 134: 925-31. 10.1016/j.jtcvs.2007.05.044.View ArticlePubMedGoogle Scholar
- Sangiorgi G, Trimarchi S, Mauriello A, Righini P, Bossone E, Suzuki T, Rampoldi V, Eagle KA: Plasma levels of metalloproteinases-9 and -2 in the acute and subacute phases of type A and type B aortic dissection. J Cardiovasc Med. 2006, 7: 307-315.View ArticleGoogle Scholar
- Joffs C, Gunasinghe HR, Multani MM, Dorman BH, Kratz JM, Crumbley AJ, Crawford FA, Spinale FG: Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases. Ann Thorac Surg. 2001, 71: 1518-23. 10.1016/S0003-4975(01)02442-0.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.